|
1
|
Ribas A and Wolchok J: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Friedenreich CM, Ryder-Burbidge C and
McNeil J: Physical activity, obesity and sedentary behavior in
cancer etiology: Epidemiologic evidence and biologic mechanisms.
Mol Oncol. 15:790–800. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Avgerinos KI, Spyrou N, Mantzoros CS and
Dalamaga M: Obesity and cancer risk: Emerging biological mechanisms
and perspectives. Metabolism. 92:121–135. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Caan BJ, Feliciano EM and Kroenke CH: The
importance of body composition in explaining the overweight paradox
in cancer-counterpoint. Cancer Res. 78:1906–1912. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Labadie BW, Liu P, Bao R, Crist M,
Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Vareki
SM, et al: BMI, irAE, and gene expression signatures associate with
resistance to immune-checkpoint inhibition and outcomes in renal
cell carcinoma. J Transl Med. 17(386)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
McQuade JL, Daniel CR, Hess KR, Mak C,
Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, et al:
Association of body-mass index and outcomes in patients with
metastatic melanoma treated with targeted therapy, immunotherapy,
or chemotherapy: A retrospective, multicohort analysis. Lancet
Oncol. 19:310–322. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yoo SK, Chowell D, Valero C, Morris LGT
and Chan TA: Outcomes among patients with or without obesity and
with cancer following treatment with immune checkpoint blockade.
JAMA Netw Open. 5(e220448)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Di Filippo Y, Dalle S, Mortier L, Dereure
O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P,
Brunet-Possenti F, et al: Relevance of body mass index as a
predictor of systemic therapy outcomes in metastatic melanoma:
Analysis of the MelBase French cohort data(✩). Ann Oncol.
32:542–551. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chen H, Wang D, Zhong Q, Tao Y, Zhou Y and
Shi Y: Pretreatment body mass index and clinical outcomes in cancer
patients following immune checkpoint inhibitors: A systematic
review and meta-analysis. Cancer Immunol Immunother. 69:2413–2424.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xu H, Cao D, He A and Ge W: The prognostic
role of obesity is independent of sex in cancer patients treated
with immune checkpoint inhibitors: A pooled analysis of 4090 cancer
patients. Int Immunopharmacol. 74(105745)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
An Y, Wu Z, Wang N, Yang Z, Li Y, Xu B and
Sun M: Association between body mass index and survival outcomes
for cancer patients treated with immune checkpoint inhibitors: A
systematic review and meta-analysis. J Transl Med.
18(235)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nie R, Chen GM, Wang Y, Yuan SQ, Zhou J,
Duan J, Liu WW, Chen S, Cai MY and Li YF: Association between body
mass index and survival outcomes in patients treated with immune
checkpoint inhibitors: Meta-analyses of individual patient data. J
Immunother Cancer. 44:371–375. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Martini DJ, Olsen TA, Goyal S, Liu Y,
Evans ST, Magod B, Brown JT, Yantorni L, Russler GA, Caulfield S,
et al: Body composition variables as radiographic biomarkers of
clinical outcomes in metastatic renal cell carcinoma patients
receiving immune checkpoint inhibitors. Front Oncol.
11(707050)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Martini DJ, Shabto JM, Goyal S, Liu Y,
Olsen TA, Evans ST, Magod BL, Ravindranathan D, Brown JT, Yantorni
L, et al: Body composition as an independent predictive and
prognostic biomarker in advanced urothelial carcinoma patients
treated with immune checkpoint inhibitors. Oncologist.
26:1017–1025. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xiao LS, Li RN, Cui H, Hong C, Huang CY,
Li QM, Hu CY, Dong ZY, Zhu HB and Liu L: Use of computed
tomography-derived body composition to determine the prognosis of
patients with primary liver cancer treated with immune checkpoint
inhibitors: a retrospective cohort study. BMC Cancer.
22(737)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kichenadasse G, Miners JO, Mangoni AA,
Rowland A, Hopkins AM and Sorich MJ: Association between body mass
index and overall survival with immune checkpoint inhibitor therapy
for advanced non-small cell lung cancer. JAMA Oncol. 6:512–518.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ahmed M, von Itzstein MS, Sheffield T,
Khan S, Fattah F, Park JY, Popat V, Saltarski JM, Gloria-McCutchen
Y, Hsiehchen D, et al: Association between body mass index, dosing
strategy, and efficacy of immune checkpoint inhibitors. J
Immunother Cancer. 9(e002349)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Collet L, Delrieu L, Bouhamama A, Crochet
H, Swalduz A, Nerot A, Marchal T, Chabaud S and Heudel PE:
Association between body mass index and survival outcome in
metastatic cancer patients treated by immunotherapy: Analysis of a
French retrospective cohort. Cancers (Basel).
13(2200)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cortellini A, Bersanelli M, Buti S,
Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di
Marino P, et al: A multicenter study of body mass index in cancer
patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors:
When overweight becomes favorable. J Immunother Cancer.
7(57)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
De Giorgi U, Procopio G, Giannarelli D,
Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli
P, et al: Association of systemic inflammation index and body mass
index with survival in patients with renal cell cancer treated with
nivolumab. Clin Cancer Res. 25:3839–3846. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Donnelly D, Bajaj S, Yu J, Hsu M, Balar A,
Pavlick A, Weber J, Osman I and Zhong J: The complex relationship
between body mass index and response to immune checkpoint
inhibition in metastatic melanoma patients. J Immunother Cancer.
7(222)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Esposito A, Marra A, Bagnardi V, Frassoni
S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F,
et al: Body mass index, adiposity and tumour infiltrating
lymphocytes as prognostic biomarkers in patients treated with
immunotherapy: A multi-parametric analysis. Eur J Cancer.
145:197–209. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tateishi A, Horinouchi H, Yoshida T,
Masuda K, Jo H, Shinno Y, Okuma Y, Goto Y, Yamamoto N and Ohe Y:
Correlation between body mass index and efficacy of anti-PD-1
inhibitor in patients with non-small cell lung cancer. Respir
Investig. 60:234–240. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Young AC, Quach HT, Song H, Davis EJ,
Moslehi JJ, Ye F, Williams GR and Johnson DB: Impact of body
composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in
melanoma. J Immunother Cancer. 8(e000821)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Martini D, Kline M, Liu Y, Shabto J,
Williams M, Khan A, Lewis C, Collins H, Akce M, Kissick H, et al:
Adiposity may predict survival in patients with advanced stage
cancer treated with immunotherapy in phase 1 clinical trials.
Cancer. 126:575–582. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Popinat G, Cousse S, Goldfarb L, Becker S,
Gardin I, Salaün M, Thureau S, Vera P, Guisier F and Decazes P:
Sub-cutaneous Fat Mass measured on multislice computed tomography
of pretreatment PET/CT is a prognostic factor of stage IV non-small
cell lung cancer treated by nivolumab. Oncoimmunology.
8(e1580128)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Magri V, Gottfried T, Di Segni M, Urban D,
Peled M, Daher S, Stoff R, Bar J and Onn A: Correlation of body
composition by computerized tomography and metabolic parameters
with survival of nivolumab-treated lung cancer patients. Cancer
Manag Res. 11:8201–8207. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Minami S, Ihara S, Tanaka T and Komuta K:
Sarcopenia and visceral adiposity did not affect efficacy of
immune-checkpoint inhibitor monotherapy for pretreated patients
with advanced non-small cell lung cancer. World J Oncol. 11:9–22.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Crombe A, Kind M, Toulmonde M, Italiano A
and Cousin S: Impact of CT-based body composition parameters at
baseline, their early changes and response in metastatic cancer
patients treated with immune checkpoint inhibitors. Eur J Radiol.
133(109340)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Faron A, Opheys NS, Nowak S, Sprinkart AM,
Isaak A, Theis M, Mesropyan N, Endler C, Sirokay J, Pieper CC, et
al: Deep learning-based body composition analysis predicts outcome
in melanoma patients treated with immune checkpoint inhibitors.
Diagnostics (Basel). 11(2314)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Baldessari C, Pecchi A, Marcheselli R,
Guaitoli G, Bonacini R, Valoriani F, Torricelli P, Reverberi L,
Menozzi R, Pugliese G, et al: Body composition and inflammation
impact in non-small-cell lung cancer patients treated by first-line
immunotherapy. Immunotherapy. 13:1501–1519. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Degens J, Dingemans AC, Willemsen ACH,
Gietema HA, Hurkmans DP, Aerts JG, Hendriks LEL and Schols A: The
prognostic value of weight and body composition changes in patients
with non-small-cell lung cancer treated with nivolumab. J Cachexia
Sarcopenia Muscle. 12:657–664. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Palleschi M, Iamurri AP, Scarpi E,
Mariotti M, Maltoni R, Mannozzi F, Barone D, Paganelli G, Casi M,
Giampalma E, et al: Computed tomography based analyses of body mass
composition in HER2 positive metastatic breast cancer patients
undergoing first line treatment with pertuzumab and trastuzumab.
Sci Rep. 12(3385)2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee JH, Hyung S, Lee J and Choi SH:
Visceral adiposity and systemic inflammation in the obesity paradox
in patients with unresectable or metastatic melanoma undergoing
immune checkpoint inhibitor therapy: A retrospective cohort study.
J Immunother Cancer. 10(e005226)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ged Y, Sanchez A, Patil S, Knezevic A,
Stein E, Petruzella S, Weiss K, Duzgol C, Chaim J, Akin O, et al:
Associations between pretreatment body composition features and
clinical outcomes among patients with metastatic clear cell renal
cell carcinoma treated with immune checkpoint blockade. Clin Cancer
Res. 28:5180–5189. 2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dahlberg SE, Schiller JH, Bonomi PB,
Sandler AB, Brahmer JR, Ramalingam SS and Johnson DH: Body mass
index and its association with clinical outcomes for advanced
non-small-cell lung cancer patients enrolled on Eastern cooperative
oncology group clinical trials. J Thorac Oncol. 8:1121–1127.
2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Katayama Y, Shimamoto T, Yamada T, Takeda
T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y,
et al: Retrospective efficacy analysis of immune checkpoint
inhibitor rechallenge in patients with non-small cell lung cancer.
J Clin Med. 9(102)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kondo T, Nomura M, Otsuka A, Nonomura Y,
Kaku Y, Matsumoto S and Muto M: Predicting marker for early
progression in unresectable melanoma treated with nivolumab. Int J
Clin Oncol. 24:323–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Qi Y, Liao D, Fu X, Gao Q and Zhang Y:
Elevated platelet-to-lymphocyte corresponds with poor outcome in
patients with advanced cancer receiving anti-PD-1 therapy. Int
Immunopharmacol. 74(105707)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang Z, Aguilar EG, Luna JI, Dunai C,
Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, et
al: Paradoxical effects of obesity on T cell function during tumor
progression and PD-1 checkpoint blockade. Nat Med. 25:141–151.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kovarik M, Hronek M and Zadak Z:
Clinically relevant determinants of body composition, function and
nutritional status as mortality predictors in lung cancer patients.
Lung Cancer. 84:1–6. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Mourtzakis M, Prado CM, Lieffers JR,
Reiman T, McCargar LJ and Baracos VE: A practical and precise
approach to quantification of body composition in cancer patients
using computed tomography images acquired during routine care. Appl
Physiol Nutr Metab. 33:997–1006. 2008.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mojibi Y, Seif F, Mojibi N, Aghamajidi A,
Mohsenzadegan M and Torang HA: Efficacy of immunotherapy in obese
patients with cancer. Immunopharmacol Immunotoxicol. 44:471–483.
2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bu LL, Yu GT, Wu L, Mao L, Deng WW, Liu
JF, Kulkarni AB, Zhang WF, Zhang L and Sun ZJ: STAT3 induces
immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res.
96:1027–1034. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Woodall MJ, Neumann S, Campbell K,
Pattison ST and Young SL: The effects of obesity on anti-cancer
immunity and cancer immunotherapy. Cancers (Basel).
12(1230)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Aguilar EG and Murphy WJ: Obesity induced
T cell dysfunction and implications for cancer immunotherapy. Curr
Opin Immunol. 51:181–186. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Han JM, Patterson SJ, Speck M, Ehses JA
and Levings MK: Insulin inhibits IL-10-mediated regulatory T cell
function: implications for obesity. J Immunol. 192:623–629.
2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Bahr I, Jahn J, Zipprich A, Pahlow I,
Spielmann J and Kielstein H: Impaired natural killer cell subset
phenotypes in human obesity. Immunol Res. 66:234–244.
2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kraakman MJ, Murphy AJ, Jandeleit-Dahm K
and Kammoun HL: Macrophage polarization in obesity and type 2
diabetes: Weighing down our understanding of macrophage function?
Front Immunol. 5(470)2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Davern M, Bracken-Clarke D, Donlon NE,
Sheppard AD, O'Connell F, Heeran AB, Majcher K, Conroy MJ, Mylod E,
Butler C, et al: Visceral adipose tissue secretome from early and
late-stage oesophageal cancer patients differentially affects
effector and regulatory T cells. J Cancer Res Clin Oncol.
149:6583–6599. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Porter SA, Massaro JM, Hoffmann U, Vasan
RS, O'Donnel CJ and Fox CS: Abdominal subcutaneous adipose tissue:
A protective fat depot? Diabetes Care. 32:1068–1075.
2009.PubMed/NCBI View Article : Google Scholar
|
